Chronic viral hepatitis and hepatitis B virus infection: stop the cancer
D Scott BowdenVictorian Infectious Diseases Reference Laboratory
Locked Bag 815
Carlton South, Vic 3053, Australia
Department of Microbiology
Monash University
Clayton, Vic 3880, Australia
Tel: (03) 9342 2615
Fax: (03) 9342 2666
Email: scott.bowden@mh.org.au
Microbiology Australia 34(3) 130-131 https://doi.org/10.1071/MA13043
Published: 4 September 2013
Abstract
Chronic viral hepatitis is a worldwide public health concern with 350 million people chronically infected with hepatitis B and 170 million with chronic hepatitis C. A substantial proportion of those infected have progressive liver disease, which can result in liver cancer, currently the world’s fifth most common cancer. Australia has experienced an increase in viral hepatitis with liver cancer becoming our fastest increasing cause of cancer mortality. Global and local strategies are in place to reduce this burden of disease.
References
[1] MacLachlan, J.H. and Cowie, B.C. (2012) Liver cancer is the fastest increasing cause of cancer death in Australians. Med. J. Aust. 197, 492–493.| Liver cancer is the fastest increasing cause of cancer death in Australians.Crossref | GoogleScholarGoogle Scholar | 23121582PubMed |
[2] Lang, T. et al. (2011) The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J. Hepatol. 55, 762–769.
| The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXhtF2hurnN&md5=414373cc545557463643e74ec7828bfeCAS | 21334391PubMed |
[3] Blumberg, B.S. et al. (1965) A ‘new’ antigen in leukemia sera. JAMA 191, 541–546.
| A ‘new’ antigen in leukemia sera.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaF2M%2FktlCntg%3D%3D&md5=579e038c0030045bbb8b2f1ca8066cdfCAS | 14239025PubMed |
[4] Chen, C.J. et al. (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295, 65–73.
| Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D&md5=f3719acb2c026171ed15fc7a849cc117CAS | 16391218PubMed |
[5] Papatheodoridis, G.V. et al. (2010) Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J. Hepatol. 53, 348–356.
| Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3cXosVGrsbY%3D&md5=f8852a3bdbae923f28fa83dd0de9c923CAS | 20483498PubMed |
[6] McClune, A.C. and Tong, M.J. (2010) Chronic hepatitis B and hepatocellular carcinoma. Clin. Liver Dis. 14, 461–476.
| Chronic hepatitis B and hepatocellular carcinoma.Crossref | GoogleScholarGoogle Scholar | 20638025PubMed |
[7] Maclachlan, J.H. et al. (2012) The burden of chronic hepatitis B virus infection in Australia, 2011. Aust. N. Z. J. Public Health , .
| The burden of chronic hepatitis B virus infection in Australia, 2011.Crossref | GoogleScholarGoogle Scholar |
[8] Lozano, R. et al. (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095–2128.
| Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.Crossref | GoogleScholarGoogle Scholar | 23245604PubMed |
[9] Viral Hepatitis (WHAA63.18) (2010) Geneva, World Health Organization.
